CytRx Corp. buy melinda
Start price
11.05.17
/
50%
€2.41
Target price
18.05.17
€3.25
Performance (%)
14.13%
End price
18.05.17
€2.75
Summary
This prediction ended on 18.05.17 with a price of €2.75. The BUY prediction by melinda finished with a performance of 14.13%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | -1,74 % | 5,98 % | 8,98 % | 49,86 % |
| iShares Nasdaq 100 | 2,81 % | 11,83 % | 38,41 % | 100,33 % |
| iShares Nikkei 225® | -0,11 % | 11,69 % | 46,68 % | 65,35 % |
| iShares S&P 500 | 0,97 % | 7,62 % | 28,14 % | 68,66 % |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Aldoxorubicine mit Doxorubicin
Krebs Weichteilsarkom feuerfester Krebs
(Vom Mitglied beendet)


